Tysabri and PML: What Monitoring Is Recommended?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This rare brain infection requires careful monitoring to detect early signs. Building on decades of pharmacovigilance research, this page reviews current guidelines for follow-up exams and what the long-term outlook entails.

Medical Evidence and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a monoclonal antibody approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations, including the statute of limitations for filing a claim, is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing reports. PML is caused by reactivation of the JC virus in immunocompromised individuals, and Tysabri's mechanism—blocking alpha-4 integrin on immune cells—impairs immune surveillance in the central nervous system, allowing the virus to proliferate. Three primary risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with cumulative exposure. The label advises that "these factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML typically includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. The label emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these precautions, PML can still occur, and outcomes are often poor, with many patients experiencing severe disability or death.

Mechanism of Action and Legal Implications for Illinois Patients

The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of lymphocyte trafficking into the brain. By blocking alpha-4 integrin, Tysabri reduces immune surveillance, allowing JC virus to replicate unchecked in oligodendrocytes. This mechanism is supported by the observation that PML risk is higher in patients with prior immunosuppressant use, which further compromises immune function. The label notes that "PML...typically only occurs in patients who are immunocompromised" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). From a risk perspective, the adequacy of warnings regarding Tysabri and PML has been a subject of litigation. The boxed warning and the TOUCH Prescribing Program—a restricted distribution system requiring patient enrollment, medication guide review, and signed consent—are designed to mitigate risk. However, some patients and their families have argued that these warnings were insufficient or that the risks were not adequately communicated before treatment. For affected patients in Illinois, settlement-related considerations may include the timeline between exposure and documented harm. PML can develop months to years after starting Tysabri, and the label states that "the duration of treatment with TYSABRI prior to onset ranged from a few months to several years" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period is important for legal claims, as the statute of limitations in Illinois for personal injury cases is generally two years from the date the injury was discovered or should have been discovered. For PML, this may be the date of diagnosis or when symptoms first appeared. Patients considering a settlement should document the timing of Tysabri treatment, onset of symptoms, and diagnosis. The label requires that patients "must be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks associated with TYSABRI, and complete and sign the Patient Enrollment Form" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This documentation can be relevant to assessing whether informed consent was obtained. In summary, Tysabri-associated PML is a serious adverse event with established risk factors and a clear mechanistic basis. For Illinois patients, the statute of limitations for filing a claim is a critical factor, and the timeline from exposure to harm must be carefully evaluated. Legal counsel should be sought to navigate settlement options and ensure timely action.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Illinois?

In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For Tysabri-associated PML, this typically means the clock starts on the date of diagnosis or when symptoms first appeared. It is crucial to consult with an attorney promptly to ensure your claim is filed within the applicable time frame.

What are the primary risk factors for developing PML while on Tysabri?

The three main risk factors for PML in Tysabri-treated patients are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.